Biocept Inc. completed a rights offering to raise about $10.4 million in net proceeds.

The San Diego-based company sold 11,587 units consisting of 11,587 shares of series A preferred stock and 2,549,140 warrants, with each warrant exercisable for one common stock at $4.53 per share.

Maxim Group LLC and Dawson James Securities Inc. acted as co-dealer-managers for the offering.

Biocept is a molecular diagnostics company that provides assays for lung, breast, gastric, colorectal, prostate and skin cancers.